Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib

Papers of special note have been highlighted as: • of interest

References

• 1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 2 Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma. World J. Gastroenterol. 22(29), 6582–6594 (2016).
  Medline CASGoogle Scholar
• 3 European Association for the Study of The Liver, European Organisation For Research and Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
  MedlineGoogle Scholar
• 4 Forner A, Reig ME, De Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 30(1), 61–74 (2010).
  Medline CASGoogle Scholar
• 5 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 11(9), 525–535 (2014).
  Medline CASGoogle Scholar
• 6 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150(4), 835–853 (2016).
  MedlineGoogle Scholar
• 7 Rognoni C, Ciani O, Sommariva S, Tarricone R. Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Value Health 20(3), 336–344 (2017).
  MedlineGoogle Scholar
• 8 Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin. Mol. Hepatol. 23(2), 109–114 (2017).
  MedlineGoogle Scholar
• 9 Biederman DM, Titano JJ, Tabori NE et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J. Vasc. Interv. Radiol. 27(6), 812–821 (2016).
  MedlineGoogle Scholar
• 10 Levi Sandri GB, Ettorre GM, Colasanti M et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg. Nutr. 6(1), 44–48 (2017).
  MedlineGoogle Scholar
• 11 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J. Hepatocell. Carcinoma 1, 163–182 (2014).
  MedlineGoogle Scholar
• 12 Ettorre GM, Levi Sandri GB, Laurenzi A et al. Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation. World J. Surg. 41(1), 241–249 (2017).
  MedlineGoogle Scholar
• 13 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. Recent Results Cancer Res. 190, 207–224 (2013).
  MedlineGoogle Scholar
• 14 Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma. Semin. Nucl. Med. 46(2), 105–108 (2016).
  MedlineGoogle Scholar
• 15 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J. Vasc. Interv. Radiol. 25(7), 1067–1073 (2014).
  MedlineGoogle Scholar
• 16 Ziogas IA, Tsoulfas G. Evolving role of sorafenib in the management of hepatocellular carcinoma. World J. Clin. Oncol. 8(3), 203–213 (2017).
  MedlineGoogle Scholar
• 17 Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851–11858 (2006).
  Medline CASGoogle Scholar
• 18 Gramenzi A, Golfieri R, Mosconi C et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 35(3), 1036–1047 (2015). • Sorafenib and transarterial radioembolization provide similar survivals in cirrhotic patients with intermediate-advanced hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 19 Golfieri R, Renzulli M, Mosconi C et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J. Vasc. Interv. Radiol. 24(4), 509–517 (2013).
  MedlineGoogle Scholar
• 20 Colombo GL, Camma C, Attili AF et al. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther. Clin. Risk Manag. 11, 1603–1612 (2015). • Costs analysis of different treatments used in intermediate and advanced hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 21 Pressiani T, Boni C, Rimassa L et al. Sorafenib in patients with Child–Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann. Oncol. 24(2), 406–411 (2013).
  Medline CASGoogle Scholar
• 22 Heimbach J, Kulik LM, Finn R et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1), 358–380 (2018).
  MedlineGoogle Scholar
• 23 Gbolahan OB, Schacht MA, Beckley EW, Laroche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J. Gastrointest. Oncol. 8(2), 215–228 (2017).
  MedlineGoogle Scholar
• 24 Rognoni C, Ciani O, Sommariva S et al. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget 7(44), 72343–72355 (2016).
  MedlineGoogle Scholar
• 25 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv. Ther. 33(5), 699–714 (2016).
  Medline CASGoogle Scholar
• 26 Bolondi L, Craxi A, Trevisani F et al. Refining sorafenib therapy: lessons from clinical practice. Future Oncol. 11(3), 449–465 (2015).
  CASGoogle Scholar
• 27 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  Medline CASGoogle Scholar
• 28 Zhang T, Ding X, Wei D et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs 21(3), 326–332 (2010).
  Medline CASGoogle Scholar
• 29 Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev. Anticancer Ther. 9(6), 739–745 (2009).
  Medline CASGoogle Scholar
• 30 Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1), 52–64 (2010).
  Medline CASGoogle Scholar
• 31 Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3), 868–878 (2011).
  MedlineGoogle Scholar
• 32 Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52(5), 1741–1749 (2010).
  Medline CASGoogle Scholar
• 33 Mazzaferro V, Sposito C, Bhoori S et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a Phase II study. Hepatology 57(5), 1826–1837 (2013).
  Medline CASGoogle Scholar
• 34 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review. World J. Gastroenterol. 22(1), 407–416 (2016).
  Medline CASGoogle Scholar